Avecho Biotechnology Past Performance
Past criteria checks 0/6
Avecho Biotechnology has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 22.5% annually. Revenues have been declining at an average rate of 20.2% per year.
Key information
18.2%
Earnings growth rate
27.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 22.5% |
| Revenue growth rate | -20.2% |
| Return on equity | -96.6% |
| Net Margin | -207.4% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08
Earnings and Revenue History
Quality Earnings: AVE is currently unprofitable.
Growing Profit Margin: AVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVE is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).
Return on Equity
High ROE: AVE has a negative Return on Equity (-96.6%), as it is currently unprofitable.